1. Scrip
  2. >>Therapy Areas

Long-Term Vitiligo Data Appear To Lay Opzelura Safety Concerns To Rest

 
• By Alaric DeArment

Incyte’s topical JAK inhibitor carries a class-wide severe safety warning and cautions against chronic use, but 52-week results could ease the way for the potential vitiligo indication.

Incyte announced updated data for topical JAK inhibitor Opzelura in vitiligo • Source: Alamy

New 52-week Phase III data for Incyte Corporation’s topical JAK inhibitor Opzelura (ruxolitinib) for vitiligo show no new safety signals, despite lingering concerns about the safety and tolerability of the JAK inhibitor class. The data also showed increased efficacy, and both the safety and efficacy could support the longer-term use that will be needed in vitiligo.

Incyte is presenting the one-year data from the TRuE-V clinical trial program at the American Academy of Dermatology annual meeting,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.